Investigating Tesamorelin's Potential to Improve Sleep Apnea in Lipodystrophy

Lipodystrophy is a rare condition characterized by abnormal fat distribution, often leading to severe metabolic complications like insulin resistance and dyslipidemia. Patients with lipodystrophy frequently experience sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA), which can significantly exacerbate cardiovascular and metabolic risks. While Tesamorelin (Egrifta) is approved for reducing excess visceral fat (fat around internal organs) in HIV-associated lipodystrophy, its direct impact on improving sleep-disordered breathing in this specific patient population was not fully understood.

As this clinical trial (NCT01788462) was withdrawn prior to completion, no specific findings or data regarding Tesamorelin's effect on sleep-disordered breathing were reported from this particular study. Therefore, no direct conclusions can be drawn about its efficacy in this context from this trial. However, existing research on Tesamorelin consistently demonstrates its ability to significantly reduce visceral adipose tissue (VAT), with studies showing an average 15-20% reduction in VAT volume over 26 weeks of treatment. This reduction in central obesity is often associated with improvements in metabolic parameters and, indirectly, could alleviate mechanical compression contributing to obstructive sleep apnea. While this specific study yielded no data, other research indicates Tesamorelin significantly reduces visceral fat, a key factor in metabolic dysfunction and potentially sleep-disordered breathing.